BTIG Maintains Buy on Palvella Therapeutics, Raises Price Target to $215
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Jeet Mukherjee maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $192 to $215.
BTIG analyst Jeet Mukherjee maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $192 to $215.